Strategic Navigators

Oral Type 2 Target Diabetes Patient Analysis

Pages: 100
Published: January 2023
Individual License: $4950
Team License: $5950
Type 2 diabetes patient, Type 2 diabetes market research, Type 2 patient analysis, Type 2 diabetes target patient

Oral Type 2 Diabetes Target Patient Analysis provides a detailed breakdown of the unique aspects of Oral Type 2 Diabetes patients taking one of the 8 branded products profiled in this report. Although not every drug is ideal for each type 2 diabetes patient, there are similarities across branded drugs that share common patient characteristics. This strategy guide breaks down oral type 2 diabetes patient characteristics and discusses how well each brand aligns with them. 

Determining the ideal treatment for a type 2 diabetes patient’s unique needs requires endocrinologists to evaluate several patient characteristics. The patient’s A1C, BMI, CKD Stage, Treatment History, and Heart Failure Stage, all play a role in which drug the doctor will prescribe.  

As new oral type 2 diabetes drugs launch into the diabetes market, drug companies need to understand how primary care providers and endocrinologists weigh these factors when making treatment decisions. It’s also important for new product launch teams to understand their brands’ ideal patient characteristics. 

The combination of patient characteristics helps determine the ‘typical’ or target patient for each oral type 2 Diabetes drug. Oral Type 2 Diabetes Target Patient Analysis shows how the type 2 patient population is broken down based on their differing needs and which oral treatments best address those needs. With a thorough analysis of patient attributes and how endocrinologists make treatment decisions, this guide provides key market insights to inform any oral type 2 diabetes brand’s launch strategy. 

Overview of Oral Type 2 Diabetes Target Patient Analysis 

As physicians evaluate their treatment options, they must factor in several key patient characteristics into their decisions. Oral Type 2 Diabetes Target Patient Analysis breaks down those characteristics and shows how endocrinologists incorporate them at the brand level. The insights contained within this report depict the type 2 diabetes target patient for each branded drug profiled in this strategy guide. 

The data focus on how US endocrinologists approach each branded Oral type 2 diabetes medication based on the following key patient’s traits: 

  • A1C 
  • BMI 
  • CKD Stage 
  • Heart Failure Class 
  • Treatment History 

Branded Treatments Analyzed  

  • Metaformin 
  • Jardiance 
  • Farxiga 
  • Sulfonylureas 
  • Januvia 
  • Invokana 
  • Rybelsus 
  • Tradjenta 
  • Thiazolidinedions TZD’s 
  • Steglatro 

Strategic Questions Answered within Type 2 Diabetes Target Patient Analysis 

  • Treatment Drivers: What are the key patient characteristics that drive HCP prescription decisions among oral type 2 diabetes treatments? 
  • Brand Ownership: What characteristics define the ‘typical’ type 2 diabetes patient receiving current oral treatments? 
  • Patient Trends: How do brands compare for patients who meet different clinical attribute criteria?  

Summary of Strategic Insights found in Oral Type 2 Diabetes Target Patient Analysis  

  • Rybelsus is seen as a medication ideal for a diabetes patient with a higher A1C and who has potentially tried two other oral medications already. This demonstrates it is likely used to establish control where others have failed. 
  • Farxiga is seen as the medication that could be used to gain added renal benefits for diabetes patients. HCPs believe the ideal patient for Farxiga is in Stage 3a CKD: 45 – 59 eGFR. 
  • Endocrinologists and primary care providers are split in which BMI category the DPP-4s are ideal for. PCPs tend to think they should be used for higher BMIs, while endocrinologists believe it should be for lower BMIs. 

Benefits of Purchasing Oral Type 2 Diabetes Target Patient Analysis 

  • Cost-efficient analysis about oral type 2 diabetes patient target trends to support your strategic marketing decisions. 
  • Insights drawn from in-depth interviews among US KOLs and surveys of more than 155 primary care providers and endocrinologists 
  • A complimentary 30-minute workshop with you (and your team) 
  • Unlimited support from Vivisum’s type 2 diabetes strategist for 1-year.  

Table of Contents 

Executive Summary – 6
Research Methodology: Robust Insights from US Physicians – 7
The Strategic Six: Key Insights About Target Patients for T2D Brands – 8
‘Typical’ Patient Map – 9
T2D Brand Target Patient Profiles – 10
Patient Share by T2 Diabetes Treatment – 11
12-month Prescribing Trends – 12 

Jardiance Patient Profile – 13
Jardiance ‘Typical’ Patient Summary – 14
Jardiance Patient ‘Typical’ A1C – 15
Jardiance Patient ‘Typical’ BMI – 16
Jardiance Patient: ‘Typical’ CKD Stage – 17
Jardiance Patient: ‘Typical’ Heart Failure Class – 18
Jardiance Patient: ‘Typical’ Treatment History – 19

Farxiga Patient Profile – 20
Farxiga ‘Typical’ Patient Summary – 21
Farxiga Patient: ‘Typical’ A1C – 22
Farxiga Patient ‘Typical’ BMI – 23
Farxiga Patient: ‘Typical’ CKD Stage– 24
Farxiga Patient: ‘Typical’ Heart Failure Class – 25
Farxiga Patient: ‘Typical’ Treatment History– 26

Januvia Patient Profile – 27
Januvia ‘Typical’ Patient Summary – 28
Januvia Patient ‘Typical’ A1C – 29
Januvia Patient ‘Typical’ BMI – 30
Januvia Patient: ‘Typical’ CKD Stage – 31
Januvia Patient: ‘Typical’ Heart Failure Class – 32
Januvia Patient: ‘Typical’ Treatment History – 33

Invokana Patient Profile – 34
Invokana ‘Typical’ Patient Summary – 35
Invokana Patient ‘Typical’ A1C – 36
Invokana Patient ‘Typical’ BMI– 37
Invokana Patient: ‘Typical’ CKD Stage – 38
Invokana Patient: ‘Typical’ Heart Failure Class – 39
Invokana Patient: ‘Typical’ Treatment History – 40

Rybelsus Patient Profile – 41
Rybelsus ‘Typical’ Patient Summary – 42
Rybelsus Patient ‘Typical’ A1C – 43
Rybelsus Patient ‘Typical’ BMI– 44
Rybelsus Patient: ‘Typical’ CKD Stage– 45
Rybelsus Patient: ‘Typical’ Heart Failure Class – 46
Rybelsus Patient: ‘Typical’ Treatment History– 47

Tradjenta Patient Profile – 48
Tradjenta ‘Typical’ Patient Summary – 49
Tradjenta Patient ‘Typical’ A1C – 50
Tradjenta Patient ‘Typical’ BMI– 51
Tradjenta Patient: ‘Typical’ CKD Stage – 52
Tradjenta Patient: ‘Typical’ Heart Failure Class – 53
Tradjenta Patient: ‘Typical’ Treatment History– 54

Steglatro Patient Profile – 55
Steglatro ‘Typical’ Patient Summary – 56
Steglatro Patient ‘Typical’ A1C – 57
Steglatro Patient ‘Typical’ BMI – 58
Steglatro Patient: ‘Typical’ CKD Stage – 59
Steglatro Patient: ‘Typical’ Heart Failure Class – 60
Steglatro Patient: ‘Typical’ Treatment History – 61

Onglyza Patient Profile – 62
Onglyza Typical’ Patient Summary – 63
Onglyza Patient ‘Typical’ A1C – 64
Onglyza Patient ‘Typical’ BMI – 65
Onglyza Patient: ‘Typical’ CKD Stage – 66
Onglyza Patient: ‘Typical’ Heart Failure Class – 67
Onglyza Patient: ‘Typical’ Treatment History– 68

Oral T2D Prescription Trends in Patient Sub-groups – 69
Oral T2D Prescription Trends by A1C – 70
A1C: Below 6 – 71
A1C: Between 6-6.9 – 72
A1C: Between 7-7.9 –73
A1C: Between 8-8.9 – 74
A1C: Between 9+-75

Oral T2D Prescription Trends by BMI – 76
BMI: Below 24.9 – 77
BMI: Between 25-29.9 – 78
BMI: Between 30-39.9 – 79
BMI: 40+ – 80

Oral T2D Prescription Trends by CKD Stage – 81
CKD Stage: Stage 1 CKD: 90 eGFR or higher – 82
CKD Stage: Stage 2 CKD: 60-89 eGFR– 83
CKD Stage: Stage 3a CKD: 45-59 eGFR– 84
CKD Stage: Stage 3b CKD: 30-44 eGFR– 85
CKD Stage: Stage 4 CKD: 15-29 eGFR– 86
CKD Stage: Stage 5 CKD: Less than 15 eGFR– 87

Oral T2D Prescription Trends by Heart Failure Class – 88
Heart Failure Class: NYHA Class I– 89
Heart Failure Class: NYHA Class II – 90
Heart Failure Class: NYHA Class III-91
Heart Failure Class: NYHA Class IV-92

Oral T2D Prescription Trends by Treatment History– 93
Treatment History: Treatment Naive– 94
Treatment History: Tried one other oral – 95
Treatment History: Tried two other orals – 96 
Treatment History: Tried three other orals – 97
Treatment History: Tried four other orals – 98

Contact – 99 


Complete the form below for a sample of this research.

Newsletter signup